I'm a cardiologist. Every day I tell patients some version of the same hard truth: the heart muscle you lost in your heart attack is gone. It won't grow back. We can open the artery, but the dead zone becomes scar — and scar doesn't beat. A 25-year-old scientist in Argentina is trying to prove me wrong. And her approach is clever enough that I'm rooting for her. Here's the problem she's attacking. When an artery blocks, heart muscle in that zone starts dying within hours. Unlike your skin or your liver, the adult human heart barely regenerates. So your body does the only thing it can — it patches the hole with fibrous scar. That scar doesn't contract. The heart pumps weaker, stretches, thins, and marches toward heart failure. This is why roughly half of heart failure patients die within five years. We manage the decline. We don't reverse it. Pilar Ferrer and her team at Amnova Biotech are going after the thing we've never solved: rebuilding the muscle itself. Their tool is inspired by one of the most quietly remarkable tissues in biology — the amniotic membrane. The sac that surrounds a baby in the womb. It's rich in regenerative and anti-inflammatory factors, and doctors already use it to heal stubborn wounds and repair the cornea. They've turned that biology into an injectable hydrogel. Cell-free — no stem cells, no animal components. It ships as a room-temperature powder, gets reconstituted, and is injected directly into the damaged heart zone, ideally during bypass surgery — the operation another Argentine, René Favaloro, gave the world. Once inside, it acts as a temporary scaffold that reengineers the healing environment: it calms the destructive inflammation, grows new blood vessels, and signals the heart's own cells to proliferate and repopulate the dead zone. Instead of surrendering to scar, the tissue gets a second chance to rebuild. The early data, in sheep — chosen because their hearts are close to ours in size and physiology — showed at 28 days: smaller infarcts, improved heart function, more new blood vessels, more dividing cardiac cells. Now the honest part, because I owe you both halves. This is early. It's preclinical. And the history of cardiology is a graveyard of therapies that looked beautiful in sheep and pigs and then failed in humans — different immune responses, different healing, different scale. Human trials aren't expected until around 2028. There is no peer-reviewed efficacy publication yet. This is a candidate to watch, not a treatment to expect. But I want to tell you why it still moves me. The whole strategy is elegant. It doesn't fight the body — it borrows the body's own oldest regenerative wisdom, the biology that builds an entire human being from scratch, and points it at a broken heart. It's cell-free, so it sidesteps the rejection and manufacturing nightmares that have stalled stem-cell approaches. It's stable at room temperature and delivered during an operation we already perform. Practical, not sci-fi. And it's the frontier I've been writing about for months, arriving from an unexpected place: the shift from managing damage to reversing it. Gene editing for cholesterol. Cell therapy for diabetes. Enzymes that erase arterial aging. And now, maybe, a gel that teaches the heart to remember how to heal. For my entire career, "the muscle is gone" has been a sentence with no appeal. A 25-year-old may be writing the appeal. Science with an Argentine accent — born in the same country that gave the world the bypass. Worth watching closely.